P1.232. Treatment Outcomes of Conversion Surgery for Advanced Esophageal Cancer Following ICI-Combined Chemotherapy
Clicks: 1
ID: 325667
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #110 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Surgical Treatment of Esophageal Cancer – long term outcomes Background Immune checkpoint inhibitor (ICI)-based combination chemotherapy for advanced esophageal cancer demonstrates high response rates, enabling conversion surgery in some cases. However, reports on the safety and prognosis of cases undergoing resection after ICI-combined chemotherapy remain limited. We retrospectively reviewed the treatment outcomes of nine Stage IV esophageal cancer patients who underwent conversion surgery after ICI-combined chemotherapy. Methods This study included 9 patients who underwent conversion surgery at our hospital between April 2023 and April 2025 following combination chemotherapy with immune checkpoint inhibitors (Nivolumab + CF or Pembrolizumab + CF). Background factors, pathological grade, best treatment response, OS/PFS, site of recurrence, and postoperative recurrence interval were retrospectively evaluated. Results Preoperative stage IVA/IVB: 3/6 patients. Average postoperative hospital stay: 19 days. Grade 3 or higher pneumonia was observed in one case. Pathological response (Grade) was: 1a: 4 cases, 1b: 1 case, 2: 3 cases, 3: 2 cases. R0 resection was achieved in 7 cases. Median OS was 20.1 months, median PFS was 11.9 months. The median survival by pathological grade was OS: Grade 1a: 25.3 months, Grade 1b: 11.0 months, Grade 2: 16.8 months, Grade 3: 22.2 months. PFS was Grade 1a: 15.7 months, Grade 1b: 3.5 months, Grade 2: 11.3 months, Grade 3: 18 months. Recurrence was observed in 8 of 9 cases. The median postoperative recurrence interval was 180 days (range: 43–502 days), and the median postoperative survival time was 440 days (range: 215–711 days). Conclusion In a review of 9 cases of advanced esophageal cancer undergoing conversion surgery after ICI-combined chemotherapy, R0 resection was achieved in 7 cases, but postoperative recurrence was high at 8 cases. There was no correlation between pathological treatment response (Grade) and recurrence-free period; some Grade 3 cases remained recurrence-free, suggesting potential for long-term survival. The median overall survival (OS) was 20 months, and the median postoperative survival was 440 days, suggesting a certain degree of long-term survival can be expected. There are no unified standards for postoperative adjuvant therapy or treatment upon recurrence, necessitating further investigation.
| Reference Key |
openalex_W7203931234
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | YUSUKE SUZUKI, Yuki Hoshi, Masatoshi Yoshizawa, Kazuhiko Hisaoka, TETSUROU TORIUMI, Yutaka Kishimoto, GEN EBARA, Yutaka Miyawaki, HIROSHI SATO, Shinichi Sakuramoto |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.380
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.